Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL-MF)
Melanoma
Melanoma
Melanoma
N/A
Zwerner, Jeffrey
VICCDERM22117
Centers for Disease Control and Prevention - Community Counts: Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting
Benign Hematologic
Benign Hematologic
Benign Hematologic
N/A
Chi, Michelle
NCBH2301-CDC-REGISTRY
Virtual 3D Intraoperative Communication System for Orthopedic Oncology: A Feasibility Study
Head/Neck
Head/Neck
Head/Neck
N/A
Topf, Michael
VICC-VDHAN23197
Blood-based, Point-of-need Assessment of CAR-T Vector Load in DLBCL Patients Undergoing Axicabtagene Ciloleucel (axi-cel) Therapy: A Multi-Site Study
Lymphoma
Lymphoma
Lymphoma
N/A
Oluwole, Olalekan
VICC-IDCTT23426
Open-Label, Long-Term Safety and Efficacy Study of Mim8 in Participants with Haemophilia A with or without Inhibitors
Not Available
III
Wheeler, Allison
NCT05685238
NCBH2401-FRONTIER4
An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Multiple Cancer Types
Neuroblastoma (Pediatrics),
Pediatric Solid Tumors
N/A
Kitko, Carrie
NCT01590680
VICCPED1249
Open-Label Safety Study in Adults and Adolescents with Haemophilia A with and without FVIII Inhibitors Switching Directly from Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis
Not Available
III
Wheeler, Allison
NCT05878938
NCBH2302-FRONTIER5
Neuroblastoma Maintenance Therapy Trial
Multiple Cancer Types
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter,
study for patients with neuroblastoma in remission. In this study subjects will receive 730
Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 250 mg/m2 BID (strata 1,
2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on
the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to
prevent recurrence.
study for patients with neuroblastoma in remission. In this study subjects will receive 730
Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 250 mg/m2 BID (strata 1,
2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on
the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to
prevent recurrence.
Endocrine,
Neuroblastoma (Pediatrics),
Neuroendocrine,
Pediatrics
II
Pastakia, Devang
NCT02679144
VICCPED16157
ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders
Not Available
IV
Wheeler, Allison
NCT04398628
NCBH2303-TRANSCENDS
REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer
Multiple Cancer Types
Miscellaneous,
Pediatrics
N/A
Esbenshade, Adam
VICCPED0710
